AcquisitionOther
Enliven Therapeutics, Inc. acquired target
Public deal record from 8-K. The source names the buyer and target, and terms are shown only when the filing or announcement discloses them.
Deal tape row
Enliven Therapeutics, Inc. -> target · $165 Million
We are thrilled to complete this merger, which will accelerate the development of our differentiated pipeline of small molecule kinase inhibitors to address existing and emerging unmet needs in oncology, said Sam Kintz, MBA, Enlivens Co-founder and Chief Ex
Open source record (SEC) ↗